<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664972</url>
  </required_header>
  <id_info>
    <org_study_id>HNCH-BC001</org_study_id>
    <nct_id>NCT04664972</nct_id>
  </id_info>
  <brief_title>The TP Regimen in the Treatment of Early Triple Negative Breast Cancer</brief_title>
  <official_title>Comparing TP (Docetaxel + Cisplatin) and TAC (Docetaxel + Doxorubicin + Cyclophosphamide) in Neoadjuvant Therapy for Operable Triple Negative Breast Cancer, A Multicenter, Randomized, Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies have shown that TNBC is sensitive to DNA crosslinking-related&#xD;
      chemotherapeutic drugs such as platinum. However, there is a lack of large sample prospective&#xD;
      clinical data to compare the efficacy of TP and EC-T / TEC regimen in the neoadjuvant&#xD;
      chemotherapy of TNBC. Besides, the application of anthracycline drugs is limited to a certain&#xD;
      extent due to the cardiotoxicity. Based on the above evidence, the researchers hope to&#xD;
      explore a more effective and safer new adjuvant therapy for TNBC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, TNBC patients were randomly divided into experimental group and control group,&#xD;
      the ratio of experimental group to control group was 1:1. The experimental group received 6&#xD;
      cycles of neoadjuvant chemotherapy (docetaxel 75 mg / m2 day 1 + cisplatin 25 mg / m2 day 1,&#xD;
      2, 3), 21 days as a cycle. The control group was treated with TAC (docetaxel 75mg / M2 +&#xD;
      adriamycin 50mg / M2 + cyclophosphamide 500mg / m2) for 6 cycles, 21 days as a cycle. To&#xD;
      compare the efficacy and safety of 6*TP (docetaxel + cisplatin) regimen and traditional 6*TAC&#xD;
      (docetaxel + doxorubicin + cyclophosphamide) regimen in neoadjuvant chemotherapy of TNBC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2018</start_date>
  <completion_date type="Anticipated">November 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 23, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The pathological complete remission rate ((pCR rate)</measure>
    <time_frame>After neoadjuvant chemotherapy+surgery, an average of 15 weeks</time_frame>
    <description>It means that there is no invasive cancer (i.e. ypT0/is, ypN0) in the resected specimens (breast + armpit) after operation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response rate</measure>
    <time_frame>Adverse events that occurred throughout the study, an average of 15 weeks</time_frame>
    <description>Clinical response rate is judged by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of PCR rate between BRCA mutation and wild type</measure>
    <time_frame>After neoadjuvant chemotherapy+surgery, an average of 15 weeks</time_frame>
    <description>Mutation of BRCA gene in triple negative breast cancer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TAC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group was treated with TAC (docetaxel 75mg/m2 + adriamycin 50mg /m2 + cyclophosphamide 500mg/m2) for 6 cycles, 21 days as a cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel +doxorubicin+ cyclophosphamide</intervention_name>
    <description>The control group was treated with TAC (docetaxel 75 mg / m2 + adriamycin 50 mg / m2 + cyclophosphamide 500 mg / m2) for 6 cycles, 21 days was a cycle.</description>
    <arm_group_label>TAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel +Cisplatin</intervention_name>
    <description>The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.</description>
    <arm_group_label>TP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18-70.&#xD;
&#xD;
          2. Clinical T2-T4c, or T1c with axillary LN+.&#xD;
&#xD;
          3. triple negative and invasive breast cancer confirmed by histopathology:&#xD;
&#xD;
             Triple negative breast cancer is defined as:&#xD;
&#xD;
               -  negative for ER and PR (IHC nuclear staining &lt; 1%).&#xD;
&#xD;
               -  Her-2 negative (IHC 0,1 + without FISH, or IHC 2 + and FISH without&#xD;
                  amplification).&#xD;
&#xD;
          4. Clinically evaluable lesions: The presence of lesions that could be evaluated by&#xD;
             ultrasound, molybdenum target or magnetic resonance imaging (optional) was within 1&#xD;
             month before randomization.&#xD;
&#xD;
          5. The function examination of organs/bone marrow showed no contraindication within 1&#xD;
             month before chemotherapy.&#xD;
&#xD;
               -  The absolute value of neutrophil count ≥2.0 × 109 / L.&#xD;
&#xD;
               -  The value of hemoglobin ≥100g/L.&#xD;
&#xD;
               -  Platelet count ≥100 × 109/L.&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 ULN (normal value online).&#xD;
&#xD;
               -  Creatinine &lt; 1.5 × ULN.&#xD;
&#xD;
               -  AST/ALT &lt; 1.5 × ULN.&#xD;
&#xD;
          6. The EF value of echocardiography≥55%.&#xD;
&#xD;
          7. The serum pregnancy test was negative for fertile woman within 14 days before&#xD;
             randomization..&#xD;
&#xD;
          8. KPS score≥80.&#xD;
&#xD;
          9. Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Metastatic breast cancer.&#xD;
&#xD;
          2. Before entering the clinical trial, patients had received chemotherapy, endocrine&#xD;
             therapy, targeted therapy, radiotherapy and so on.&#xD;
&#xD;
          3. The patient had dual primary malignancies, except for skin cancer, which was treated.&#xD;
&#xD;
          4. Combined with other serious and uncontrollable medical diseases, the researchers&#xD;
             judged that the disease had chemotherapy contraindications.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenzhen Liu</last_name>
    <role>Study Director</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dechuang Jiao</last_name>
    <phone>13598004327</phone>
    <email>jiaodechuang@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhenzhen Liu</last_name>
    <phone>13603862755</phone>
    <email>liuzhenzhen73@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiao DeChuang</last_name>
      <phone>13598004327</phone>
      <email>jiaodechuang1982@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jingyang Zhang</last_name>
      <phone>18236966956</phone>
      <email>18236966956@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Liuzhenzhen</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

